These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 11280550

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Interleukin-18 and its binding protein in patients with inflammatory bowel disease during remission and exacerbation.
    Naftali T, Novick D, Gabay G, Rubinstein M, Novis B.
    Isr Med Assoc J; 2007 Jul; 9(7):504-8. PubMed ID: 17710779
    [Abstract] [Full Text] [Related]

  • 23. Intraperitoneal cytokine productions and their relationship to peritoneal sepsis and systemic inflammatory markers in patients with inflammatory bowel disease.
    Yamamoto T, Umegae S, Kitagawa T, Matsumoto K.
    Dis Colon Rectum; 2005 May; 48(5):1005-15. PubMed ID: 15785898
    [Abstract] [Full Text] [Related]

  • 24. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission.
    Valentini L, Schaper L, Buning C, Hengstermann S, Koernicke T, Tillinger W, Guglielmi FW, Norman K, Buhner S, Ockenga J, Pirlich M, Lochs H.
    Nutrition; 2008 May; 24(7-8):694-702. PubMed ID: 18499398
    [Abstract] [Full Text] [Related]

  • 25. CARD15 mutations in Dutch familial and sporadic inflammatory bowel disease and an overview of European studies.
    van der Linde K, Boor PP, Houwing-Duistermaat JJ, Crusius BJ, Wilson PJ, Kuipers EJ, de Rooij FW.
    Eur J Gastroenterol Hepatol; 2007 Jun; 19(6):449-59. PubMed ID: 17489054
    [Abstract] [Full Text] [Related]

  • 26. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
    Folwaczny C, Wiebecke B, Loeschke K.
    Am J Gastroenterol; 1999 Jun; 94(6):1551-5. PubMed ID: 10364024
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Natural anticoagulant protein levels in Turkish patients with inflammatory bowel disease.
    Cakal B, Gokmen A, Yalinkilic M, Cakal E, Ayaz S, Nadir I, Ozin Y, Dagli U, Ulker A.
    Blood Coagul Fibrinolysis; 2010 Mar; 21(2):118-21. PubMed ID: 20040858
    [Abstract] [Full Text] [Related]

  • 29. Serum zinc, copper, and selenium levels in inflammatory bowel disease: effect of total enteral nutrition on trace element status.
    Fernández-Bañares F, Mingorance MD, Esteve M, Cabré E, Lachica M, Abad-Lacruz A, Gil A, Humbert P, Boix J, Gassull MA.
    Am J Gastroenterol; 1990 Dec; 85(12):1584-9. PubMed ID: 2123604
    [Abstract] [Full Text] [Related]

  • 30. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features.
    Annese V, Piepoli A, Perri F, Lombardi G, Latiano A, Napolitano G, Corritore G, Vandewalle P, Poulain D, Colombel JF, Andriulli A.
    Aliment Pharmacol Ther; 2004 Nov 15; 20(10):1143-52. PubMed ID: 15569117
    [Abstract] [Full Text] [Related]

  • 31. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease.
    Dotan I, Fishman S, Dgani Y, Schwartz M, Karban A, Lerner A, Weishauss O, Spector L, Shtevi A, Altstock RT, Dotan N, Halpern Z.
    Gastroenterology; 2006 Aug 15; 131(2):366-78. PubMed ID: 16890590
    [Abstract] [Full Text] [Related]

  • 32. Platelet activating factor in stool from patients with ulcerative colitis and Crohn's disease.
    Hocke M, Richter L, Bosseckert H, Eitner K.
    Hepatogastroenterology; 1999 Aug 15; 46(28):2333-7. PubMed ID: 10521992
    [Abstract] [Full Text] [Related]

  • 33. Defense mechanisms in inflammatory bowel disease.
    Hyphantis TN, Triantafillidis JK, Pappa S, Mantas C, Kaltsouda A, Cherakakis P, Alamanos Y, Manousos ON, Mavreas VG.
    J Gastroenterol; 2005 Jan 15; 40(1):24-30. PubMed ID: 15692786
    [Abstract] [Full Text] [Related]

  • 34. Elevated markers of thrombin generation and fibrinolysis in patients with active and quiescent ulcerative colitis.
    Zezos P, Papaioannou G, Nikolaidis N, Patsiaoura K, Vassiliadis T, Mpoumponaris A, Giouleme O, Evgenidis N.
    Med Sci Monit; 2009 Nov 15; 15(11):CR563-72. PubMed ID: 19865055
    [Abstract] [Full Text] [Related]

  • 35. [Carbonyl groups content in serum proteins as an indicator of disease activity in children with inflammatory bowel diseases and its dependence on the other markers of inflammatory process].
    Krzesiek E, Pytrus T, Kosmowska A, Iwańczak B.
    Pol Merkur Lekarski; 2008 Dec 15; 25(150):455-9. PubMed ID: 19205373
    [Abstract] [Full Text] [Related]

  • 36. Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease.
    Andoh A, Tsujikawa T, Hata K, Araki Y, Kitoh K, Sasaki M, Yoshida T, Fujiyama Y.
    Am J Gastroenterol; 2005 Sep 15; 100(9):2042-8. PubMed ID: 16128950
    [Abstract] [Full Text] [Related]

  • 37. Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease.
    Koutroubakis IE, Xidakis C, Karmiris K, Sfiridaki A, Kandidaki E, Kouroumalis EA.
    Eur J Clin Invest; 2006 Feb 15; 36(2):127-32. PubMed ID: 16436095
    [Abstract] [Full Text] [Related]

  • 38. Circulating and mucosal concentrations of tumour necrosis factor and inhibitor(s) in chronic inflammatory bowel disease.
    Nielsen OH, Brynskov J, Bendtzen K.
    Dan Med Bull; 1993 Apr 15; 40(2):247-9. PubMed ID: 8495600
    [Abstract] [Full Text] [Related]

  • 39. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease.
    Walker TR, Land ML, Kartashov A, Saslowsky TM, Lyerly DM, Boone JH, Rufo PA.
    J Pediatr Gastroenterol Nutr; 2007 Apr 15; 44(4):414-22. PubMed ID: 17414136
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.